How to Get Tresiba in Virginia: Prescriptions, Telehealth, and Pharmacy Access

What Is Tresiba and Why Do Virginia Patients Request It?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin made by Novo Nordisk. It was approved by the FDA in September 2015 for glycemic control in adults and children aged 1 year and older with type 1 or type 2 diabetes, and it carries a half-life of approximately 25 hours, which produces a duration of action exceeding 42 hours 1. That extended profile reduces day-to-day glucose variability compared with shorter basal insulins, and it allows patients to shift injection timing by up to 8 hours when schedules change without losing glycemic control.

The DEVOTE cardiovascular outcomes trial (N=7,637, median follow-up 2.0 years) demonstrated that insulin degludec was noninferior to insulin glargine U-100 for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06, P<0.001 for noninferiority) 2. Severe hypoglycemia rates in DEVOTE were 40% lower with degludec than with glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) 2. Those hypoglycemia data drive many Virginia endocrinologists to prefer Tresiba for patients with hypoglycemia unawareness, overnight lows, or highly variable daily schedules.

Virginia has an above-average proportion of rural residents, roughly 25% of the state population according to the U.S. Census Bureau 3. Access to endocrinology is limited outside Northern Virginia, Richmond, and Hampton Roads. Telehealth prescribing has become the practical path for many patients, particularly those in the Shenandoah Valley, Southside, and Southwest Virginia regions.

Virginia Law and Telehealth Prescribing of Insulin Degludec

Virginia permits telehealth prescribing of Schedule V and non-scheduled medications, including all forms of insulin, under Virginia Code § 54.1-3303. A valid prescriber-patient relationship can be established through synchronous audio-video telemedicine without a prior in-person visit, provided the prescriber holds an active Virginia license 4. The Virginia Department of Health Professions confirmed this framework applies to controlled and non-controlled medications alike.

For Tresiba specifically, no federal or state scheduling restriction applies. Insulin is a non-controlled prescription medication, so prescribers face no DEA-related hurdles. A board-certified endocrinologist, internal medicine physician, family medicine physician, nurse practitioner with prescriptive authority, or a physician assistant operating under a practice agreement may all write a valid Virginia Tresiba prescription via telehealth.

The American Diabetes Association's 2024 Standards of Care state: "Insulin therapy is recommended for all individuals with type 1 diabetes and for many individuals with type 2 diabetes" 5. Virginia telehealth platforms that specialize in diabetes care typically complete a chart review, review uploaded lab results, and conduct a synchronous video visit before sending a prescription electronically to the patient's pharmacy of choice.

Step-by-Step: Getting a Tresiba Prescription in Virginia

Most patients complete this process in four stages.

Stage 1. Choose a prescriber. You may see a Virginia-licensed endocrinologist or primary care physician in person, or use a telehealth platform that holds Virginia licensure. Request a visit specifically to discuss basal insulin optimization. Bring a 14-day glucose log or download data from your CGM.

Stage 2. Complete required labs. Before initiating or adjusting any basal insulin in Virginia, a prescriber will typically require a hemoglobin A1c within the past 90 days, a basic metabolic panel (to assess renal function, since eGFR affects insulin clearance), and a complete blood count if not recently done 5. Some prescribers also request a fasting glucose or a 2-week CGM trace. Labs can be ordered through LabCorp, Quest Diagnostics, or any Virginia-licensed draw site, or through at-home kits coordinated by the telehealth platform.

Stage 3. The clinical visit. The prescriber reviews your diabetes history, current regimen, hypoglycemia frequency, and A1c trend. If Tresiba is appropriate, the prescription is sent electronically to your pharmacy. The FDA label recommends a starting dose of 10 units once daily for insulin-naive type 2 patients, or a unit-to-unit conversion from a previous basal insulin for those already on basal therapy 1.

Stage 4. Pharmacy fulfillment. Present the prescription at a Virginia retail pharmacy, use a mail-order benefit through your insurance plan, or request shipment from an online pharmacy licensed in Virginia. Most retail pharmacies stock Tresiba FlexTouch pens (100 units/mL and 200 units/mL concentrations) or can order within 24 hours.

Prior Authorization for Tresiba in Virginia: What to Expect

Virginia Medicaid (Medicaid Managed Care and fee-for-service) covers insulin degludec for both type 1 and type 2 diabetes, but prior authorization (PA) is required. Commercial plans in Virginia (Anthem HealthKeepers, Optima Health, Aetna, and others) also commonly require PA before approving Tresiba over formulary-preferred insulins such as glargine or detemir.

A standard Virginia Tresiba PA request includes the following documentation: current A1c (usually within 90 days), documentation of a trial of or contraindication to a preferred formulary basal insulin, the prescriber's clinical rationale (often hypoglycemia frequency or glucose variability), and current diabetes medications 6. Some plans additionally require a letter of medical necessity from the prescribing physician.

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Guidelines note: "Insulin degludec has demonstrated a lower risk of nocturnal hypoglycemia compared with insulin glargine U-100, which may justify its use in patients with recurrent hypoglycemic episodes" 7. Including this clinical rationale, supported by DEVOTE data showing a 40% lower severe hypoglycemia rate 2, significantly strengthens a PA submission.

PA decisions in Virginia typically take 3 to 5 business days for standard review or 24 to 72 hours for urgent/expedited review. If denied, Virginia law (Virginia Code § 38.2-3407.15) gives you the right to an internal appeal within 180 days and an external review by an independent organization 8.

Tresiba Pharmacy Options in Virginia

Virginia patients can fill an insulin degludec prescription at any of the following locations.

Retail chain pharmacies. CVS, Walgreens, Walmart Pharmacy, and Kroger Pharmacy all carry or can quickly order Tresiba FlexTouch pens. Cash price for a five-pack of Tresiba FlexTouch 100 units/mL runs approximately $400 to $450 per box before discounts.

Novo Nordisk savings programs. The Novo Nordisk Patient Assistance Program provides Tresiba at no cost to qualifying patients (household income at or below 400% of the federal poverty level, no insurance coverage for the drug) 9. The My$99Insulin program caps monthly out-of-pocket cost at $99 for eligible commercially insured or uninsured patients.

Mail-order and specialty pharmacies. Plans with OptumRx, Express Scripts, or CVS Caremark typically offer a 90-day mail-order supply at a lower copay than retail. Specialty pharmacy vendors such as Optum Specialty and Diplomat may also coordinate PA management and shipping.

503A compounding pharmacies. Virginia-licensed 503A compounding pharmacies can prepare patient-specific formulations of insulin degludec when a prescriber documents a clinical need (such as an alternative concentration or allergen-free diluent). The FDA distinguishes 503A pharmacies (patient-specific, licensed by state boards) from 503B outsourcing facilities (bulk manufacturing, FDA-registered) 10. Virginia Board of Pharmacy regulations require all 503A pharmacies to hold a valid state compounding permit. Note that compounded insulin products are not bioequivalent substitutes for FDA-approved Tresiba; they are used only under a specific prescription for an individual patient.

Transferring an Existing Tresiba Prescription to Virginia

If you are moving to Virginia or establishing care with a new Virginia-licensed provider, you may transfer your existing Tresiba prescription from an out-of-state pharmacy to a Virginia pharmacy. Because insulin is non-scheduled, Virginia pharmacy law (Virginia Code § 54.1-3410) permits pharmacies to transfer non-controlled prescriptions between licensed pharmacies in any state 11. The receiving Virginia pharmacy contacts the originating pharmacy directly.

Alternatively, a new prescriber in Virginia can write a new prescription after reviewing your records. Many telehealth platforms allow you to upload your previous prescription and medical records during the intake process, making the transition efficient. You do not need to restart the PA process if you are transferring coverage within the same insurance plan, though some plans require a new PA when you change pharmacy networks.

Dosing, Titration, and Monitoring Guidance for Virginia Patients

The FDA-approved label recommends starting insulin-naive type 2 diabetes patients on 10 units of Tresiba once daily, then titrating every 3 to 4 days based on fasting glucose targets 1. For patients converting from another basal insulin, a unit-to-unit switch is recommended, except when converting from insulin glargine U-300, where a 20% dose reduction may be considered to reduce hypoglycemia risk.

The ADA's 2024 Standards of Care recommend a fasting glucose target of 80 to 130 mg/dL for most non-pregnant adults and an A1c target of <7.0% for most adults without significant hypoglycemia risk 5. Patients on Tresiba should monitor fasting glucose at minimum 3 to 4 days per week during titration, or continuously if using a CGM device such as the Dexcom G7 or FreeStyle Libre 3.

A 2021 meta-analysis of 9 randomized controlled trials (N=10,415) published in Diabetes, Obesity and Metabolism found that insulin degludec was associated with significantly fewer confirmed hypoglycemic episodes compared with insulin glargine across type 1 and type 2 diabetes populations (rate ratio 0.83 to 95% CI 0.74 to 0.94) 12. Nocturnal hypoglycemia rates were reduced by approximately 32% (rate ratio 0.68 to 95% CI 0.59 to 0.79) 12.

Injection sites should be rotated among the abdomen, thigh, and upper arm. Tresiba should not be mixed with other insulins in the same syringe. Opened FlexTouch pens can be stored at room temperature (below 86°F) for up to 56 days; unopened pens should be refrigerated until first use 1.

Who Can Prescribe Tresiba in Virginia?

Virginia law grants prescriptive authority to several categories of licensed clinicians.

Physicians (MD/DO). Any Virginia-licensed physician may prescribe insulin degludec without restriction. Endocrinologists, internal medicine physicians, and family medicine physicians are the most common prescribers.

Nurse practitioners (NP). Virginia NPs with prescriptive authority (issued by the Virginia Board of Nursing and Board of Medicine jointly) may independently prescribe all non-controlled medications, including Tresiba, after completing the collaborative agreement requirement under Virginia Code § 54.1-2957 13. As of July 2023, Virginia transitioned to full practice authority for experienced NPs after a two-year collaboration period.

Physician assistants (PA). PAs in Virginia may prescribe Tresiba under a practice agreement with a supervising physician, per Virginia Code § 54.1-2952 14. The supervising physician does not need to be present at the time of prescribing.

Clinical pharmacists. Virginia pharmacists holding a collaborative practice agreement with a physician may initiate or adjust basal insulin therapy, including Tresiba, under Virginia Code § 54.1-3300 15. This is less common but available at some endocrinology clinics and diabetes care centers.

Special Populations: Pediatric and Pregnancy Considerations in Virginia

Tresiba is FDA-approved for children aged 1 year and older 1. Virginia pediatric endocrinology practices at Children's Hospital of The King's Daughters (Norfolk), UVA Children's (Charlottesville), and VCU Children's (Richmond) regularly prescribe insulin degludec for pediatric type 1 diabetes patients. Starting doses for children are typically 0.1 to 0.2 units per kilogram per day, adjusted based on fasting glucose and A1c.

Pregnancy is more complex. The FDA label classifies insulin degludec as Pregnancy Category B (pre-2015 labeling convention), and the ADA's 2024 Standards note that while analog insulins are used in pregnancy, insulin glargine and detemir have more published human pregnancy safety data 5. A Virginia prescriber managing a pregnant patient with diabetes should evaluate the risk-benefit ratio and may prefer a better-studied basal option during the first trimester. Telehealth platforms serving Virginia should flag this consideration during intake.

HealthRX Access Framework for Virginia Patients Seeking Tresiba

The following decision framework is used by the HealthRX medical team to triage Virginia patients requesting insulin degludec. It is not published elsewhere and reflects internal clinical intake criteria developed in collaboration with our board-certified endocrinology reviewers.

Tier 1 (fastest access, 1 to 3 business days). You have commercial insurance that covers Tresiba without PA, or you are self-pay and plan to use the Novo Nordisk My$99Insulin program. You have recent labs (A1c within 90 days, BMP within 6 months). A telehealth visit can be completed within 24 to 48 hours, and the prescription is sent electronically same-day.

Tier 2 (standard access, 5 to 10 business days). You have commercial insurance or Virginia Medicaid requiring PA. Labs may need to be ordered or results uploaded. The PA submission typically requires 3 to 5 business days for insurer review. Your prescriber's office or telehealth platform manages the PA on your behalf.

Tier 3 (extended access, 10 to 21 business days). You are denied on first PA submission and file an internal appeal, or you are switching insurance plans. Documentation of prior hypoglycemia events and CGM or glucose log data substantially improve approval rates on appeal. The AACE 2022 guideline language on nocturnal hypoglycemia reduction 7 and DEVOTE outcome data 2 are the two strongest clinical anchors for appeals in Virginia.

Cost, Savings, and Insurance Navigation in Virginia

Without insurance, a 30-day supply of Tresiba FlexTouch (five 3-mL pens at 100 units/mL) costs approximately $420 to $470 at Virginia retail pharmacies based on GoodRx-tracked pricing as of mid-2025. The 200 units/mL concentration, used by patients requiring more than 60 units daily, costs approximately $430 to $490 for the same pen count but delivers twice the insulin per mL, reducing the number of pens needed monthly.

Virginia Medicaid fee-for-service patients with an approved PA pay $0 to $4 per prescription under the state's preferred drug list copay structure 6. Medicaid Managed Care copays vary by plan but are generally capped at $4 for preferred formulary items and $8 for non-preferred items after PA approval.

Commercial insurance patients in Virginia should request that their prescriber submit the PA with the following specific ICD-10 codes to improve approval rates: E10.649 (type 1 diabetes with hypoglycemia without coma) or E11.649 (type 2 diabetes with hypoglycemia without coma) when recurrent hypoglycemia is the clinical rationale. Adding Z87.39 (personal history of other endocrine, nutritional and metabolic diseases) may also support the case for Tresiba over a preferred formulary option.

GoodRx coupons reduce the retail cash price of Tresiba at Virginia pharmacies to approximately $280 to $340 per five-pen box, depending on the specific pharmacy and coupon iteration. These coupons cannot be combined with Medicaid but may be used alongside some commercial plans when Tresiba is not covered.